Zacks Investment Research
09 Sept 2026, 19:50 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Novartis' late-stage HARBOR study for del-desiran in treating myotonic dystrophy type 1 failed to meet its primary endpoint. — Failure of a Phase III trial for a key pipeline asset typically leads to immediate downward valuation pressure and loss of potential future revenue.
-0.60This event marks the second late-stage pipeline setback for Novartis within a five-day window, following the failure of pelacarsen. — Repeated failures in late-stage trials can signal systemic R&D issues and reduce investor confidence in the company's near-term growth catalyst pipeline.
-0.40The FDA has granted Priority Review for Novartis' application for delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy. — Priority Review accelerates the path to potential commercialization, providing a positive offset to recent pipeline losses.
+0.30Which stocks this story touches
Continue reading
5 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
